-69.9%
ENPH vs GSK
+48.7%
-118.7%
-81.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.4% | +0.2% | -5.6% | -5.5% |
| 7D | +3.4% | -3.6% | +7.0% | +4.8% |
| 30D | -10.3% | -5.9% | -4.3% | -8.1% |
| 3M | -31.4% | -4.3% | -27.1% | -30.9% |
| 6M | -10.1% | -10.8% | +0.7% | -6.3% |
| YTD | +14.6% | +1.8% | +12.8% | +13.3% |
| 1Y | -3.2% | +23.5% | -26.7% | -12.7% |
| All | -69.9% | +48.7% | -118.7% | -76.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling